TCR2 Therapeutics Inc.
TCRR · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $58,831 | $38,762 | $69,517 | $111,844 |
| - Cash | $14,446 | $32,746 | $54,006 | $44,211 |
| + Debt | $5,978 | $53,761 | $58,229 | $63,783 |
| Enterprise Value | $50,363 | $59,777 | $73,740 | $131,416 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$32,810 | -$1,656 | -$30,213 | -$30,471 |
| % Margin | – | – | – | – |
| Net Income | -$40,399 | -$60,505 | -$30,594 | -$31,601 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.03 | -1.56 | -0.79 | -0.82 |
| % Growth | 34% | -97.5% | 3.7% | – |
| Operating Cash Flow | -$40,010 | -$24,957 | -$25,839 | -$19,531 |
| Capital Expenditures | -$158 | -$2,441 | -$4,823 | -$6,211 |
| Free Cash Flow | -$40,168 | -$27,398 | -$30,662 | -$25,742 |